Axiom Biosciences is considering an initial public offering in Hong Kong, a rare step for an American biotechnology firm, according to Bloomberg.
The listing would help Axiom tap China’s booming clinical development capabilities.
STOCKS | US-Based Axiom Seeks Hong Kong IPO to Tap China Biotech Boom
2026-07-21 11:05:46
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Elon Musk Says SpaceX Data Will Train Grok’s Next Model
